CLINICAL OUTCOMES ASSOCIATED WITH THE TREATMENT OF NEWLY DIAGNOSED STAGE IV CLASSICAL HODGKIN LYMPHOMA IN PRACTICE SETTINGS IN FRANCE, GERMANY AND THE UNITED KINGDOM

Introduction: Classical Hodgkin lymphoma (cHL) is a hematologic malignancy with poor prognosis for advanced-stage patients who do not respond well to first line (1L) therapy. 1L treatment patterns for cHL are well-known. However, clinical outcomes associated with 1L treatments in a community setting have not been routinely assessed. This study examines clinical outcomes associated with commonly used 1L systemic regimens used to treat Stage IV cHL in France (FRA), Germany (DE), and the United Kingdom (UK) in a community setting. Methods: Hematologists and oncologists (N=47) from FRA, DE, and the UK retrospectively identified patients diagnosed with Stage IV cHL and treated with 1L systemic therapy: doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD); doxorubicin, vinblastine, and dacarbazine (AVD); dose-escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPescalated); BEACOPP. Descriptive statistics examined patient demographics and 1L systemic regimens. Bivariate analyses (chi-square) compared second line (2L) treatment patterns by 1L systemic regimen. Unadjusted progression-free survival (PFS) was assessed with Kaplan Meier curves and PFS by 1L systemic regimen was compared with a log-rank test. Disease progression was defined as the occurrence of progression, relapse, 2L treatment, or death. Results: Patients in 1L (N=78) were administered ABVD (57.7%), AVD (10.3%), BEACOPPescalated (24.4%), or BEACOPP (7.6%). Mean (SD) age at initial diagnosis for the aggregate patient sample was 49.5 (16.1) years, which was mostly male (71.8%) and distributed across FRA (30.8%), DE (26.9%), and the UK (42.3%). Outcomes and 2L treatment patterns are presented in Table 1. Median follow-up was 25.5 months (range: 14.0-80.3 months). Unadjusted PFS by 1L systemic regimen is presented in Figure 1. Median (95% CI) PFS was 32 months (16-43 months) for 1L ABVD patients, 13 months (0-not estimable) for 1L AVD patients, not estimable for 1L BEACOPPescalated patients, and 17 months (7-37 months) for 1L BEACOPP patients. Conclusions: These findings demonstrate that treatment outcomes in the clinical practice setting with commonly used treatment regimens may be different than those observed in clinical trials. These findings underscore the unmet medical need in patients with cHL and the importance of novel treatment regimens. Keywords: chemotherapy; classical Hodgkin lymphoma (cHL). Disclosures: Dalal, M: Employment Leadership Position: This study was funded by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA. Mehul Dalal is an employee of Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA. Hentrich, M: Consultant Advisory Role: This study was funded by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA. Marcus Hentrich received a consultancy fee for medical expertise on this project from Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA. Stamatoullas-Bastard, A: Consultant Advisory Role: This study was funded by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA. Aspasia Stamatoullas-Bastard received a consultancy fee for medical expertise on this project from Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA. Zagadailov, E: Employment Leadership Position: This study was funded by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA. Erin Zagadailov is an employee of Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA. Gautam, A: Employment Leadership Position: This study was funded by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA. Ashish Gautam is an employee of Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA. Way, N: Research Funding: This study was funded by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA. Nate Way is an employee of Kantar Health, who received funding to conduct this study from Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA. Cambron-Mellott, M: Research Funding: This study was funded by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA. M. Janelle Cambron-Mellott is an employee of Kantar Health, who received funding to conduct this study from Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA. Illidge, T: Consultant Advisory Role: This study was funded by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA. Timothy Illidge received a consultancy fee for medical expertise on this project from Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.